Skip to main content
    I

    Inspire Medical Systems Inc (INSP)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $59.07
    -2.03 (-3.32%)

    Market Cap: $1.77B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Inspire Medical Systems Inc (INSP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Inspire Medical Systems reported revenue of $911.98M for the fiscal year ended Dec 31, 2025, up 13.6% from the year before. That year, net income was $145.42M with a net margin of 15.9%, operating cash flow was $116.98M and free cash flow was $78.48M. The quarter ended Sep 30, 2026 had revenue of $206.69M and net income of -$24.39M.

    Revenue and Margins

    The operating margin was 5.6% in the fiscal year ended Dec 2025, the highest of the 9 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $16.43M, a compound annual rate of 56.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$911.98M+13.6%85.4%5.6%15.9%
    Dec 2024$802.80M+28.5%84.7%4.5%6.7%
    Dec 2023$624.80M+53.2%84.5%-6.4%-3.4%
    Dec 2022$407.86M+74.7%83.8%-11.7%-11.0%
    Dec 2021$233.39M+102.3%85.7%-17.1%-18.0%
    Dec 2020$115.38M+40.6%84.7%-48.7%-49.6%
    Dec 2019$82.05M+62.2%83.4%-42.5%-40.5%
    Dec 2018$50.59M+77.1%80.1%-40.3%-43.1%
    Dec 2017$28.57M+73.9%78.9%-56.0%-61.3%
    Dec 2016$16.43MN/A76.2%-105.0%-112.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 171.8% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$911.98M$802.80M$624.80M$407.86M$233.39M$115.38M$82.05M$50.59M$28.57M$16.43M
    Cost of revenue$133.22M$122.99M$96.58M$66.11M$33.28M$17.62M$13.64M$10.06M$6.02M$3.90M
    Gross profit$778.76M$679.82M$528.22M$341.74M$200.12M$97.76M$68.41M$40.54M$22.55M$12.52M
    Research and development$103.17M$114.13M$116.54M$68.64M$37.35M$26.09M$12.84M$7.39M$6.19M$7.09M
    Operating income$50.95M$36.08M-$40.27M-$47.59M-$39.85M-$56.21M-$34.90M-$20.38M-$16.00M-$17.25M
    Net income$145.42M$53.51M-$21.15M-$44.88M-$42.04M-$57.20M-$33.24M-$21.83M-$17.51M-$18.53M
    EBITDA$59.37MN/A-$40.09M-$45.79M-$38.73M-$55.22MN/A-$20.08M-$15.36M-$17.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$206.69M$200.58M$204.58M$269.08M$224.50M$217.09M$201.32M$239.72M$203.19M$195.88M$164.01M$192.51M
    Gross profit$177.86M$171.46M$176.91M$233.01M$192.73M$182.41M$170.61M$203.73M$170.79M$166.04M$139.25M$164.45M
    Operating income-$28.72M-$514.00K-$1.12M$46.11M$9.64M-$3.32M-$1.49M$31.88M$14.32M$5.10M-$15.22M$9.30M
    Net income-$24.39M$314.00K-$11.29M$136.09M$9.93M-$3.59M$2.99M$35.22M$18.50M$9.79M-$10.01M$14.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.16M by $102.66M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$907.32M$808.38M$676.81M$564.88M$295.08M$281.19M$181.25M$200.08M$25.09M$13.12M
    Current assets$583.65M$630.81M$593.74M$530.03M$268.54M$269.87M$170.64M$199.28M$24.10M$12.25M
    Cash and equivalents$104.81M$150.15M$185.54M$441.59M$214.47M$190.52M$22.86M$97.29M$8.96M$6.68M
    Total liabilities$126.16M$118.69M$104.30M$68.87M$66.04M$51.44M$41.42M$36.08M$23.76M$19.72M
    Short-term debt$2.16M$1.75MN/A$1.34M$9.19M$0$828.00KN/A$16.46M$3.31M
    Long-term debtN/AN/AN/AN/A$15.80M$24.75M$24.52M$24.93M$16.46M$12.38M
    Shareholder equity$781.16M$689.70M$572.51M$496.01M$229.05M$229.75M$139.84M$164.00M$1.33M-$6.61M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$953.03M$925.99M$911.38M$918.49M$807.72M$802.19M$730.81M$808.38M$796.19M$728.39M$685.84M$676.81M
    Total liabilities$126.08M$100.41M$119.04M$137.33M$141.26M$124.38M$95.07M$118.69M$99.63M$90.32M$96.82M$104.30M
    Cash and equivalents$190.80M$127.76M$98.93M$104.81M$112.84M$106.93M$53.88M$150.15M$147.51M$188.03M$175.42M$185.54M
    Shareholder equity$826.95M$825.58M$792.34M$781.16M$666.46M$677.81M$635.74M$689.70M$696.56M$638.07M$589.02M$572.51M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 67.1% of operating cash flow. Share repurchases came to 223.0% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$116.98M$130.25M$24.65M$11.57M-$20.12M-$53.05M-$32.85M-$18.69M-$15.79M-$17.95M
    Capital expenditures$38.50M$39.12M$23.63M$9.10M$4.67M$2.46M$2.74M$250.00K$412.00K$306.00K
    Free cash flow$78.48M$91.12M$1.02M$2.47M-$24.79M-$55.50M-$35.59M-$18.94M-$16.20M-$18.25M
    Share repurchases$175.02M$75.00M$0$0N/AN/AN/AN/AN/AN/A
    Investing cash flow$21.45M-$113.12M-$294.82M-$19.60M$29.14M$86.63M-$43.56M-$83.39M-$7.60M-$306.00K
    Financing cash flow-$183.45M-$52.39M$13.95M$235.08M$14.95M$134.06M$1.96M$190.38M$25.66M$12.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$46.43M$23.23M$12.85M$52.47M$68.53M$2.68M-$6.70M$69.18M$52.28M-$78.00K$8.86M$17.27M
    Capital expenditures$7.54M$9.16M$9.73M$10.66M$10.44M$9.00M$8.41M$7.03M$8.01M$12.39M$11.70M$8.03M
    Free cash flow$38.88M$14.07M$3.12M$41.81M$58.09M-$6.31M-$15.11M$62.15M$44.28M-$12.47M-$2.84M$9.23M
    Last 12 quarters

    Frequently Asked Questions About INSP

    What is Inspire Medical Systems' annual revenue?

    Inspire Medical Systems reported revenue of $911.98M for the fiscal year ended Dec 31, 2025.

    How fast is Inspire Medical Systems' revenue growing?

    Revenue was up 13.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 30.8%.

    Is Inspire Medical Systems profitable?

    Yes. Inspire Medical Systems reported net income of $145.42M for the fiscal year ended Dec 31, 2025, with a net margin of 15.9%.

    How much free cash flow does INSP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $116.98M minus capital expenditures of $38.50M produced free cash flow of $78.48M.

    How much debt does Inspire Medical Systems have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.16M and cash and equivalents of $104.81M.